In semaglutides case: Novo Nordisk obtained a genus patent covering semaglutide as a compound, with the usual 20year protection.[19][20] Later, it filed a second patent on a closely related version intended to prolong exclusivity, along with a series of secondary patents on formulations and delivery devices.[21][14] The Delhi High Court, examining Novos suit against Indian companies like Dr Reddys, held that this second patent amounted to double patenting and evergreening , which is barred under Indias Patents Act (Section 3(d)).[20][22][19] Because India explicitly prohibits evergreening, the court refused to block Indian firms from manufacturing and exporting semaglutide while maintaining restrictions on incountry sales tied to remaining patent issues.[23][20] Key point: Courts in India have openly described parts of Novos semaglutide strategy as evergreeningextending monopoly protection beyond what a single invention normally deserves

Generally, Mounjaro prescription near you for diabetes requires a confirmed diagnosis, which impacts insurance coverage
Other possible side effects include GI issues and loss of appetite
Specifically, be concerned if weight loss stalls completely for more than 3 weeks despite caloric deficit, if appetite suppression is noticeably weaker than during initial weeks, if you do not notice any thermogenic effect, or if your weekly weight loss rate drops below half of what clinical trials show for your dose level
It is strictly prohibited to administer these products to humans or animals under any circumstances
Gupta A, Das A, Majumder K, Arora N, Mayo HG, Singh PP, et al